New research shows improvement in components of reading, including decoding and vocabulary, among children treated with atomoxetine compared to a placebo. This new treatment was also associated with significant reductions in symptoms of attention-deficit/hyperactivity disorder in children with both dyslexia and ADHD or ADHD alone, as reported in the study published in Journal of Child and Adolescent Psychopharmacology.
Psychopharmacological intervention shows promise in treating children with dyslexia #dyslexia
Last updated:
There are new treatments for ADHD proven by using placebos.
The study which was conducted at the University of North Carolina by DR. Steven Hooper at the School of Medicine evaluated reading ability and ADHD symptoms in children aged 10-16 years who had dyslexia or ADHD, or only ADHD and received either atomoxetine or placebo for 16 weeks. The authors report their results in the article “Atomoxetine Treatment on Reading and Phonological Skills in Children with Dyslexia or Attention-Deficit/Hyperactivity Disorder and Co morbid Dyslexia in a Randomized, Placebo-Controlled Trial.
Author Quote
"
“Treatments for dyslexia are essential for the millions of children who suffer from this disorder. This unique study offers a potential promising psychopharmacological intervention for the treatment of dyslexia,” says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.
"Key Takeaways:
1
Recent research suggests that medication may help dyslexics.
2
10-16 years old were examined in the college study.
3
Treatment is crucial for dyslexics.
